Ligand-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulations of New β-Estrogen Receptor Activators with Potential for Pharmacological Obesity Treatment
Molecules · 2023
DOI: 10.3390/molecules28114389 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Domingo Méndez-Álvarez und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa 88710, Mexico. Hauptthemen laut MEDLINE: Molecular Dynamics Simulation, Receptors, Estrogen. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Secretaría de Investigación y Posgrado del Instituto Politécnico Nacional.
Abstract (Originalsprache)
Obesity is a pandemic and a serious health problem in developed and undeveloped countries. Activation of estrogen receptor beta (ERβ) has been shown to promote weight loss without modifying caloric intake, making it an attractive target for developing new drugs against obesity. This work aimed to predict new small molecules as potential ERβ activators. A ligand-based virtual screening of the ZINC15, PubChem, and Molport databases by substructure and similarity was carried out using the three-dimensional organization of known ligands as a reference. A molecular docking screening of FDA-approved drugs was also conducted as a repositioning strategy. Finally, selected compounds were evaluated by molecular dynamic simulations. Compounds 1 (−24.27 ± 0.34 kcal/mol), 2 (−23.33 ± 0.3 kcal/mol), and 6 (−29.55 ± 0.51 kcal/mol) showed the best stability on the active site in complex with ERβ with an RMSD < 3.3 Å. RMSF analysis showed that these compounds do not affect the fluctuation of the Cα of ERβ nor the compactness according to the radius of gyration. Finally, an in silico evaluation of ADMET showed they are safe molecules. These results suggest that new ERβ ligands could be promising molecules for obesity control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa 88710, Mexico.
- Laboratorio de Biomedicina Molecular 2, Escuela Nacional de Medicina y Homeopatía, Instituto Politécnico Nacional, Ciudad de México 07320, Mexico.
ORCID-Profile: Laurence A Marchat, Gildardo Rivera
Förderung
- Secretaría de Investigación y Posgrado del Instituto Politécnico Nacional
Zitieren
APA
Méndez-Álvarez, D., Torres-Rojas, M. F., Lara-Ramirez, E. E., Marchat, L. A., & Rivera, G. (2023). Ligand-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulations of New β-Estrogen Receptor Activators with Potential for Pharmacological Obesity Treatment. Molecules. https://doi.org/10.3390/molecules28114389
Vancouver
Méndez-Álvarez D, Torres-Rojas MF, Lara-Ramirez EE, Marchat LA, Rivera G. Ligand-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulations of New β-Estrogen Receptor Activators with Potential for Pharmacological Obesity Treatment. Molecules. 2023. doi:10.3390/molecules28114389
BibTeX
@article{Mndezlvarez2023,
author = {Méndez-Álvarez, Domingo and Torres-Rojas, Maria F and Lara-Ramirez, Edgar E and Marchat, Laurence A and Rivera, Gildardo},
title = {Ligand-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulations of New β-Estrogen Receptor Activators with Potential for Pharmacological Obesity Treatment},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28114389}
}
EUVIMED